Choosing and evaluating randomisation methods in clinical trials: a qualitative study.

Focus groups Qualitative RCTs Randomisation

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
20 Mar 2024
Historique:
received: 07 07 2023
accepted: 22 02 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: epublish

Résumé

There exist many different methods of allocating participants to treatment groups during a randomised controlled trial. Although there is research that explores trial characteristics that are associated with the choice of method, there is still a lot of variety in practice not explained. This study used qualitative methods to explore more deeply the motivations behind researchers' choice of randomisation, and which features of the method they use to evaluate the performance of these methods. Data was collected from online focus groups with various stakeholders involved in the randomisation process. Focus groups were recorded and then transcribed verbatim. A thematic analysis was used to analyse the transcripts. Twenty-five participants from twenty clinical trials units across the UK were recruited to take part in one of four focus groups. Four main themes were identified: how randomisation methods are selected; researchers' opinions of the different methods; which features of the method are desirable and ways to measure method features. Most researchers agree that the randomisation method should be selected based on key trial characteristics; however, for many, a unit standard is in place. Opinions of methods were varied with some participants favouring stratified blocks and others favouring minimisation. This was generally due to researchers' perception of the effect these methods had on balance and predictability. Generally, predictability was considered more important than balance as adjustments cannot be made for it; however, most researchers felt that the importance of these two methods was dependent on the design of the study. Balance is usually evaluated by tabulating variables by treatment arm and looking for perceived imbalances, predictability was generally considered much harder to measure, partly due to differing definitions. There is a wide variety in practice on how randomisation methods are selected and researcher's opinions on methods. The difference in practice observed when looking at randomisation method selection can be explained by a difference in unit practice, and also by a difference in researchers prioritisation of balance and predictability. The findings of this study show a need for more guidance on randomisation method selection.

Sections du résumé

BACKGROUND BACKGROUND
There exist many different methods of allocating participants to treatment groups during a randomised controlled trial. Although there is research that explores trial characteristics that are associated with the choice of method, there is still a lot of variety in practice not explained. This study used qualitative methods to explore more deeply the motivations behind researchers' choice of randomisation, and which features of the method they use to evaluate the performance of these methods.
METHODS METHODS
Data was collected from online focus groups with various stakeholders involved in the randomisation process. Focus groups were recorded and then transcribed verbatim. A thematic analysis was used to analyse the transcripts.
RESULTS RESULTS
Twenty-five participants from twenty clinical trials units across the UK were recruited to take part in one of four focus groups. Four main themes were identified: how randomisation methods are selected; researchers' opinions of the different methods; which features of the method are desirable and ways to measure method features. Most researchers agree that the randomisation method should be selected based on key trial characteristics; however, for many, a unit standard is in place. Opinions of methods were varied with some participants favouring stratified blocks and others favouring minimisation. This was generally due to researchers' perception of the effect these methods had on balance and predictability. Generally, predictability was considered more important than balance as adjustments cannot be made for it; however, most researchers felt that the importance of these two methods was dependent on the design of the study. Balance is usually evaluated by tabulating variables by treatment arm and looking for perceived imbalances, predictability was generally considered much harder to measure, partly due to differing definitions.
CONCLUSION CONCLUSIONS
There is a wide variety in practice on how randomisation methods are selected and researcher's opinions on methods. The difference in practice observed when looking at randomisation method selection can be explained by a difference in unit practice, and also by a difference in researchers prioritisation of balance and predictability. The findings of this study show a need for more guidance on randomisation method selection.

Identifiants

pubmed: 38509527
doi: 10.1186/s13063-024-08005-z
pii: 10.1186/s13063-024-08005-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199

Informations de copyright

© 2024. The Author(s).

Références

Hariton E, Locascio JJ. Randomised Controlled trials - the gold standard for effectiveness research. BJOG. 2018;125(13):1716.
doi: 10.1111/1471-0528.15199 pubmed: 29916205 pmcid: 6235704
Egbewale BE. Random allocation in controlled clinical trials: a review. J Pharm Pharm Sci. 2014;17:248–53.
doi: 10.18433/J3SW36 pubmed: 24934553
Lim C-Y, In J. Randomization in Clinical studies. Korean J Anesthesiol. 2005;72(3):221–32.
doi: 10.4097/kja.19049
Agency EM. Guideline on adjustment for baseline covariates in clinical trials. 2015.
Nguyen T-L, Collins GS, Lamy A, Devereaux PJ, Daurès J-P, Landais P, et al. Simple randomization did not protect against bias in smaller trials. J Clin Epidemiol. 2017;84:105–13.
doi: 10.1016/j.jclinepi.2017.02.010 pubmed: 28257927
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin Trials. 1988;9(4):327–44.
doi: 10.1016/0197-2456(88)90047-5 pubmed: 3203524
Bruce CL, Juszczak E, Ogollah R, Partlett C, Montgomery A. A systematic review of randomisation method use in RCTs and association of trial design characteristics with method selection. BMC Med Res Methodol. 2022;22:314.
doi: 10.1186/s12874-022-01786-4 pubmed: 36476324 pmcid: 9727841
McPherson GC, Campbell MK, Elbourne DR. Use of randomisation in clinical trials: a survey of UK practice. Trials. 2012;13:198.
doi: 10.1186/1745-6215-13-198 pubmed: 23101457 pmcid: 3522058
Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.
doi: 10.1186/1471-2288-13-117 pubmed: 24047204 pmcid: 3848812
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
doi: 10.1093/intqhc/mzm042 pubmed: 17872937
Atkinson AC. Optimum Biased Coin Designs for Sequential Clinical Trials with Prognostic factors. Biometrika. 1982;69(1):61–7.
doi: 10.1093/biomet/69.1.61
Senn S. Controversies concerning randomization and additivity in clinical trials. Stat Med. 2004;23:3729–53.
doi: 10.1002/sim.2074 pubmed: 15580598
Senn S, Atkinson A, Whitehead J. Discussion. Stat Med. 1999;18:1753–5.
doi: 10.1002/(SICI)1097-0258(19990730)18:14<1753::AID-SIM211>3.0.CO;2-5
Treasure T, MacRae KD. Minimisation: the platinum standard for trials. BMJ. 1998;317:362–3.
doi: 10.1136/bmj.317.7155.362 pubmed: 9694748 pmcid: 1113668
Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics. 1979;35:183–97.
doi: 10.2307/2529944 pubmed: 497334
Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. J Hum Reprod Sci. 2011;4:8–11.
doi: 10.4103/0974-1208.82352 pubmed: 21772732 pmcid: 3136079
Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. BMJ. 2010;340:c332. https://doi.org/10.1136/bmj.c332 .
Brown S, Thorpe H, Hawkins K, Brown J. Minimization - reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med. 2005;24:3715–27.
doi: 10.1002/sim.2391 pubmed: 16320287
Kang M, Ragan BG, Park J-H. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008;43(2):215–21.
doi: 10.4085/1062-6050-43.2.215 pubmed: 18345348 pmcid: 2267325
Hilgers R-D, Uschner D, Rosenberger WF, Heussen N. ERDO - a framework to select an appropriate randomization procedure for clinical trials. BMC Med Res Methodol. 2017;17:159.
doi: 10.1186/s12874-017-0428-z pubmed: 29202708 pmcid: 5715815
Uschner D, Schindler D, Heussen N, Hilgers R-D. randomizeR: An R Package for the Assessment and Implementation of Randomization in Clinical Trials. J Stat Softw. 2018;85:1–22.
doi: 10.18637/jss.v085.i08
Chabouis HF, Chabouis F, Gillaizeau F, Durieux P, Chatellier G, Ruse ND, et al. Randomization in clinical trials: stratification or minimization? The HERMES free simulation software. Clin Oral Investig. 2014;18:25–34.
doi: 10.1007/s00784-013-0949-8 pubmed: 23455573
Kennedy ADM, Togerson DJ, Campbell MK, Grant AM. Subversion of allocation concealment in a randomised controlled trial: a historical case study. Trials. 2017;18:204.
doi: 10.1186/s13063-017-1946-z pubmed: 28464922 pmcid: 5414185

Auteurs

Cydney L Bruce (CL)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK. cydney.bruce1@nottingham.ac.uk.

Mais Iflaifel (M)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Alan Montgomery (A)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Reuben Ogollah (R)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Kirsty Sprange (K)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Christopher Partlett (C)

Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.

Classifications MeSH